Pfizer granted FDA breakthrough therapy designation for Trumenba (meningococcal Group B vaccine) for the prevention of invasive meningococcal B disease in children aged 1 to 9 years

23 April 2018 - Pfizer today announced that Trumenba (meningococcal Group B vaccine) received breakthrough therapy designation from the U.S. FDA ...

Read more →

All aged-care homes must offer staff flu vaccinations, Turnbull government orders

23 April 2018 - All aged-care home will be required to provide flu vaccinations to all staff after more than ...

Read more →

2018 influenza vaccines now available

18 April 2018 - More than 4.5 million Australians who are most at risk of getting sick during this year’s flu ...

Read more →

New Zealand Pharmaceutical Schedule - 1 April 2018

1 April 2018 - The April 2018 issue of the New Zealand Pharmaceutical Schedule is now available and in effect. ...

Read more →

2018 seasonal influenza vaccines

27 March 2018 - This year, four quadrivalent and two trivalent influenza vaccines will be available. ...

Read more →

EU recommendations for 2018/2019 seasonal flu vaccine composition

26 March 2018 - EU advice based on WHO recommendations. ...

Read more →

Shingrix approved in Europe and Japan for the prevention of shingles in adults aged 50 and over

23 March 2018 - The only shingles vaccine to achieve ≥90% efficacy across all age groups studied. ...

Read more →

Shingrix, shingles vaccine for older adults, now available at CVS

19 March 2018 - Pharmacy-retail giant CVS announced on Friday that it will now carry the shingles vaccine Shingrix in ...

Read more →

Trumenba (meningococcal Group B vaccine) now available in Canada

6 March 2018 - Trumenba is the only vaccine indicated for adolescents and young adults aged 18 to 25 to prevent ...

Read more →

Statement from FDA Commissioner on FDA’s ongoing efforts to help improve effectiveness of influenza vaccines

26 February 2018 - The current influenza season has been especially difficult, causing widespread illness that has affected all fifty ...

Read more →

GSK receives European approval for expanded indication for Fluarix Tetra (influenza vaccine) for ages six months and older

15 February 2018 - GSK today announced the expanded indication for Fluarix Tetra (quadrivalent influenza vaccine) has been approved in Europe ...

Read more →

Influenza vaccine for 2018 season

12 February 2018 - PHARMAC is pleased to announce a quadrivalent influenza vaccine will be supplied for the 2018 influenza ...

Read more →

GSK’s meningitis B vaccine Bexsero receives breakthrough therapy designation from US FDA for prevention of invasive meningococcal disease in children 2-10 years of age

7 February 2018 - GlaxoSmithKline today announced that it has received breakthrough therapy designation from the U.S. FDA for its meningitis ...

Read more →

Free meningococcal vaccine backed at national level

3 January 2018 - Two weeks ago there was no funding for a vaccine that protects against four strains of ...

Read more →

Takeda's Zika vaccine gets U.S. FDA's 'fast track' status

30 January 2018 - Japan’s Takeda Pharmaceutical Co Ltd said on Monday the U.S. FDA had granted ‘fast track’ status to ...

Read more →